Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doramapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 10/20 | 1.00 |
| ▸ | TNF | P01375 | 7/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 3/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 3/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 3/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | MUSK | O15146 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | HSPB1 | P04792 | 1/20 | 1.00 |
| ▸ | PRKCB | P05771 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doramapimod SCHEMBL129721 | 1.00 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| Doramapimod SCHEMBL10320344 | 0.99 | MAPK14 (0.98) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL20876996 | 0.96 | MAPK14 (0.93) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL14185084 | 0.95 | MAPK14 (0.91) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL6330722 | 0.95 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL295302 | 0.95 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL5967533 | 0.94 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL13857350 | 0.94 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL295792 | 0.94 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL29594033 | 0.94 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20250367183-A1 | SUBSTANCE FOR PROMOTING REGENERATION AND REPAIR OF ORGANS OF MAMMALS AND USE THEREOF | INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-12-04 | — | — | US | claimed |
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | claimed |
| US-20250295668-A1 | METHODS FOR INDUCING COLANIC ACID BIOSYNTHESIS | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-09-25 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-12403132-B2 | Methods of treating bone marrow failure syndromes and compositions for use in the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-09-02 | — | — | US | claimed |
| EP-4602148-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | Peking University (CN) | 2025-08-20 | — | — | EP | claimed |
| US-12370180-B2 | P38 map kinase inhibitors for treating Friedreich's ataxia | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-29 | — | — | US | claimed |
| EP-3980012-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-04-13 | — | — | EP | claimed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | claimed |
| WO-2022065859-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | 성균관대학교산학협력단 | 2022-03-31 | — | — | WO | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | claimed |
| WO-2022042527-A1 | SMALL-MOLECULE DRUG FOR TREATING DISEASES RELATED TO INNER EAR AND INTESTINAL EPITHELIAL TISSUE INJURIES | 北京大学 | 2022-03-03 | — | — | WO | claimed |
| CN-114085803-A | Establishment of organoid culture systems with regenerative properties | 北京大学 | 2022-02-25 | — | — | CN | claimed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | claimed |
| WO-2022034031-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | KINARUS AG (CH) | 2022-02-17 | — | — | WO | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | MAPK14 1005/4885TNF 4207/4885MAPK13 1642/4885 |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | MAPK14 1645/4885TNF 1914/4885MAPK13 902/4885 |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | MAPK1, MAP2K1, MAP2K6 | MAPK14 14/4885TNF 147/4885MAPK13 45/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | MAPK14 560/4885TNF 1862/4885MAPK13 475/4885 |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | MAPK14 3891/4885TNF 4848/4885MAPK13 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.